Tolterodine: Selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers

Drugs in R and D

Volumn 3, Issue 2, 2002, Pages 75-81

  Chapple, Christopher R ^a   Nilvebrant, Lisbeth ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b Nilvebrant Pharma Consulting AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TOLTERODINE; BENZHYDRYL DERIVATIVE; CRESOL; MANDELIC ACID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

ACCOMMODATION; ADULT; AREA UNDER THE CURVE; ARTICLE; BLADDER CAPACITY; BLADDER FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG SELECTIVITY; EYE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER; XEROSTOMIA; BLADDER; DRUG EFFECT; MIDDLE AGED;

ADULT; BENZHYDRYL COMPOUNDS; CRESOLS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EYE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY BLADDER;

EID: 0036367642     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203020-00001     Document Type: Article

References (32)

1. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 1999; 44: 56-66
2. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000; 11: 13-27
3. Caulfield MP. Muscarinic receptors - characterization, coupling, and function. Pharmacol Ther 1993; 58: 319-79
4. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 48: 531-56
5. Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90
6. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-62
7. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-93
8. Nilvebrant L, Andersson K-E, Gillberg P-G, et al. Tolterodine -a new bladder selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207
9. Stahl MM, Ekstiröm B, Sparf B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14: 647-55
10. Brynne N, Stahl MMS, Hallén B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287-95
11. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 (6A Suppl): 90-6
12. Abrams P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-10
13. Drutz H, Appell RA, Gleason D. et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283-9
14. Yamaguchi O, Shisda K, Tamura K, et al. Evaluation of mRNAs encoding for muscarinic receptor subtypes in human detrusor muscle. J Urol 1996; 56: 1208-13
15. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995; 273: 959-66
16. Vanderheyden P, Gies JP, Ebinger G, et al. Human M1-, M2-and M3-muscarinic cholinergic receptors binding characteristics of agonists and antagonists. J Neurol Sci 1990; 97: 67-80
17. Mei L, Roeske WR, Izutsu KT, et al. Characterization of muscarinic acetylcholine receptors in human labial salivary glands. Eur J Pharmacol 1990; 176: 367-70
18. Gil DW, Breen TS, Bogardus AM, et al. Muscarinic receptors in human ciliary muscle identified by polymerase chain reaction (PCR) and immunoprecipitation [abstract no. 47]. Life Sci 1993; 52: 573
19. Hegde SS, Chopin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in-vitro and in-vivo. Br J Pharmacol. 1997; 120: 1409-18
20. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999; 64: 419-28
21. Nilvebrant L, Hallen B, Larsson G. Tolterodine -a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129-36
22. Gillberg P-G, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine and those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998; 349: 285-92
23. Nilvebrant L. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors. Acta Pharmacol Toxicol 1986; 59 Suppl I: 1-45
24. Nagao M, Kaneko S, Hirota T, et al. Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in the conscious dog. Folia Pharmacologica Jpn 1999; 113: 157-66
25. Waldeck K, Larsson N, Andersson K-E. Comparison of oxybutynin and its active metabolite in the human detrusor and parotid gland. J Urol 1997; 157: 1093-7
26. Physician Desk Reference, 54th ed. Montville (NJ): Detrol product information. Medical Economics Company, Inc., 2000: 2439-41
27. Jackson S. The patient with an overactive bladder -symptoms and quality of life issues. Urology 1997; 50 (6A Suppl): 18-22
28. Gupta N, Drance SM, McAllister R, et al. Localization of M3 muscarinic receptor subtype and mRNA in the human eye. Ophthalmic Res 1994; 26: 207-13
29. Zhang X, Hernandez MR, Yang H, et al. Expression of muscarinic receptor subtype mRNA in the human ciliary muscle. Invest Ophthalmol Vis Sci 1995; 36: 1645-57
30. Pang IH, Matsumoto S, Tamm E, et al. Characterization of muscarinic receptor involvement in human ciliary muscle cell function. J Ocul Pharmacol. 1997; 10: 125-36
31. Zetterström C. Effects of adrenergic drugs on accommodation and distant refraction in daylight and darkness. Acta Ophthalmol (Copenh) 1988; 66: 58-64
32. Diokno AC, Wells TJ, Brink CA. Comparison of self-reported voided volume with cystometric bladder capacity. J Urol 1987; 137: 698-700